Virological response to adefovir monotherapy and the risk of adefovir resistance

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 30

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

270

HTML

2124

Figures (1-1)

145

Tables (1-5)

153

Sum=2692

Aug 14, 2011 (publication date) through Apr 24, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Aug 14, 2011; 17(30): 3526-3530
Published online Aug 14, 2011. doi: 10.3748/wjg.v17.i30.3526

Table 2 Patterns of ADV-resistant mutations at weeks 48 and 96 after ADV monotherapy in LAM-resistant patients

LAM: Lamivudine; ADV: Adefovir dipivoxil; rtA181V/T and/or rtN236T: ADV-resistant strain.

Citation: Sinn DH, Lee HI, Gwak GY, Choi MS, Koh KC, Paik SW, Yoo BC, Lee JH. Virological response to adefovir monotherapy and the risk of adefovir resistance. World J Gastroenterol 2011; 17(30): 3526-3530
URL: https://www.wjgnet.com/1007-9327/full/v17/i30/3526.htm
DOI: https://dx.doi.org/10.3748/wjg.v17.i30.3526